Source: Business Standard
On Friday, the stock of AstraZeneca Pharma India went up by over 2 percent after the company received approval from India’s drug regulator to use its medicine, Benralizumab (traded as Fasenra) for a new indication.
The Central Drugs Standard Control Organisation (CDSCO) has allowed AstraZeneca to import and sell the injection for Benralizumab 30 mg/ml for another medical condition. The medicine is now allowed to be prescribed to treat eosinophilic granulomatosis with polyangiitis, a rare disease characterized by inflammation of blood vessels affecting multiple organs.
Stock Market Response
After the announcement, AstraZeneca’s share price rose as much as 2.14% to ₹8,089 during the day. As of 1:30 PM, the share price was trading higher 1.26% or ₹8,018.90, while the BSE Sensex was down 0.21% at 81,461.57.
In a filing to the stock exchange, AstraZeneca said, “This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) for an additional indication.”
Second Drug Approval This Week
Earlier in the week, AstraZeneca also received CDSCO approval for another drug, Osimertinib (sold as TAGRISSO). Osimertinib is meant to treat a certain type of lung cancer (stage III non-small cell lung cancer) in certain specific gene mutations in patients after they have completed therapy.
Upcoming Financial Results
AstraZeneca Pharma’s Board of Directors is meeting today to approve its financial results for the fourth quarter and full financial year 2025 (FY25). The Board will likely also consider declaring a dividend.
Regarding AstraZeneca Pharma India
AstraZeneca Pharma India is a local subsidiary of the global AstraZeneca group, which is a British-Swedish company that was formed in 1999. The company has operated in India for more than 45 years, and specializes in the research, development, and sale of medicines for cancer, heart disease, gastric problems, infectious disease, lung disease, and many others.
Additionally, AstraZeneca Pharma India is known for its efforts in developing the Oxford–AstraZeneca COVID-19 vaccine. The company uses data science and artificial intelligence to assist in research and development activities.
Market Position
The market capitalization of AstraZeneca Pharma India is ₹20,037.38 crore. AstraZeneca Pharma India is currently in the BSE500 index. The stock has reached a 52-week high of ₹9,199 and a 52-week low of ₹5,415.55.
